cytoreductive surgery(crs) plus hyperthermic intraperitoneal chemotherapy(hipec) with lobaplatin in advanced and recurrent epithelial ovarian cancer

Conditions: Ovarian Cancer; Ovary Neoplasm; Ovarian Neoplasms; Epithelial Ovarian Cancer; Ovarian Cancer, Epithelial; Hyperthermic Intraperitoneal Chemotherapy(HIPEC)

Summary: a phase iii prospective study with the primary objective to compare the efficacy and safety of hipec( hyperthermic intraperitoneal chemotherapy). the target population for this study is patients with primary or recurrence ovarian, peritoneal or fallopian tube cancers undergoing crs( cytoreductive surgery). patients will be divided into two groups. group a will undergo crs plus hipec and then go on to receive standard platinum-based combination doublet intravenous chemotherapy. group b will undergo crs and then go on to intravenous chemotherapy.

this is a phase iii prospective study with the primary objective to compare the efficacy and safety of hipec. the target population for this study is patients with primary or recurrence ovarian, peritoneal or fallopian tube cancers undergoing crs. 'platinum-sensitive' recurrence is defined as recurrence 6 months after the completion of the primary platinum-based chemotherapy. a single dose of lobaplatin 40mg/m2 will be administered via hipec , and will be administered at the time of surgery, 3 days after surgery and 5 days after surgery. patients of group a will undergo crs plus hipec and then go on to receive standard platinum-based combination doublet intravenous chemotherapy (carboplatin and paclitaxel, carboplatin and gemcitabine, or carboplatin and liposomal doxorubicin) for 6 cycles. patients of group b will undergo crs and then go on to intravenous chemotherapy.

Eligibility criteria:
inclusion criteria: * age 18-75 * karnofsky performance status \>50 or world health organization performance score \< 2 * primary or recurrence ovarian, peritoneal or fallopian tube epithelial cancer; first intra-abdominal recurrence without distant metastasis (including: unique resectable pleural metastasis which are platinum-sensitive; resectable single lymphatic metastasis retroperitoneal or inguinal) * preoperative platinum-based chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, gemcitabine, trabectedin or topotecan) * lesion can be removed completely or residual disease \< 0.5 cm * last chemotherapy finished no more than 12 weeks after surgery * no hepatic function damage * white blood cell count ≥3.5\*10\^9/l; platelet count ≥80\*10\^9/l; hemoglobin ≥90g/l * no contraindication of surgery and anesthesia * life expectancy ≥ 3 months exclusion criteria: * age \ 75 * no history of other cancer * platinum allergy * distant metastasis * used anti-angiogenic drug within 8 weeks * possibility of more than two resection of alimentary canal * recurrence \< 6 months after primary treatment * histologic type: non epithelial origin * infection out of control * follow-up unable to carry on (geographic or psychic) * cardiac insufficiency or respiratory insufficiency * has received hipec already * being in other clinical study * pregnancy or lactation period

Keywords: hyperthermic intraperitoneal chemotherapy epithelial ovarian cancer